Donepezil improved PDD symptoms first 14 weeks and then decline continued.
Anavex did a 14 week study just like the dopenazil and has not shown results due to possible negative results past week 14 therefore Missling chose to hide them until after ALZ TLD
One Obstacle: 92% of the high dose improved, no Parkinson drug has ever achieved that, not even close. I see no obstacles as A2-73 Blarcamesine is approved for both PD and PDD.
One obstacle. Glacial management's inability to get a p3 trial even STARTED after more than one year. WhereTF is it already?
Market Data 
Markets 
AI
